Impact of delayed addition of PD-1/PD-L1 inhibitors to chemotherapy on outcomes in patients with extensive-stage small cell lung cancer
In patients with ES-SCLC, delayed administration of PD-1/PD-L1 inhibitors during the second to fourth chemotherapy cycles improves survival outcomes compared to concurrent administration during the first cycle, with a similar safety profile. These results suggest that, in specific patient populations, delayed immunotherapy may improve survival outcomes by optimizing patient condition or treatment response.
Authors
- Shuangqing Lu
- Zhuoran Sun (ORCID: https://orcid.org/0000-0001-9509-6399)
- Ke‐Qing Zhao (ORCID: https://orcid.org/0000-0001-5703-3768)
- Dawei Chen (ORCID: https://orcid.org/0000-0002-4015-2557)
- Xiaoyang Zhai (ORCID: https://orcid.org/0000-0002-2924-221X)
- Hui Zhu
- Chao Wang (ORCID: https://orcid.org/0000-0001-7885-9673)
Institutions
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251356919
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province